Malaria is common in areas such as Africa, South America, and Southern Asia. This medicine is not effective against all strains of malaria. Plaquenil itchy skin Plaquenil itchy hands and feet Plaquenil reduces preeclampsia However, at disease progression in arm B dabrafenib plus trametinib, hydroxychloroquine 200 mg twice daily will be added to the standard treatment and treatment will be continued until disease progression, unacceptable treatment related toxicity or patient's refusal to continue study treatment. Phase I Trial of Trametinib and Hydroxychloroquine in Patients With Advanced Pancreatic Cancer THREAD Summary The purpose of this phase I trial is to study the side effects and best dose of hydroxychloroquine when given together with trametinib in treating patients with pancreatic cancer that has spread to nearby tissue, lymph nodes or other places in the body and cannot be removed by surgery. Phase 1 To determine the maximum tolerated dose MTD and preliminary safety of hydroxychloroquine HCQ when administered in conjunction with oral dabrafenib and trametinib D+T in patients with advanced BRAF mutant melanoma. Phase 2 To assess the clinical efficacy of HCQ+D+T by 1 year PFS rate. 1.2 Secondary Objectives Taking hydroxychloroquine long-term or at high doses may cause irreversible damage to the retina of your eye. Hydroxychloroquine is also an antirheumatic medicine and is used to treat symptoms of rheumatoid arthritis and discoid or systemic lupus erythematosus. Trametinib hydroxychloroquine Abstract LB-254 Combined inhibition of MEK and autophagy., Phase I Trial of Trametinib and Hydroxychloroquine in. How does hydroxychloroquine work for arthritisMacular oct plaquenil toxicityDoes plaquenil cause kidney problems Dabrafenib, Trametinib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma BAMM The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U. S. Federal Government. Dabrafenib, Trametinib and Hydroxychloroquine in Patients.. UPCC 02614 The BAMM Trial BRAF, Autophagy and MEK.. Trametinib and Hydroxychloroquine in Treating Patients With Pancreatic.. Hydroxychloroquine is a 4-aminoquinoline in use for more than 30 years for the treatment of malaria, rheumatoid arthritis, and systemic lupus erythematosus. A recent study shows that the combination of MEK inhibitor trametinib and hydroxychloroquine led to a striking disease response in a patient with pancreatic cancer. Trametinib and Hydroxychloroquine in Treating Patients With Pancreatic Cancer THREAD The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U. S. Federal Government. FREQUENT SUBCLINICAL MACULAR CHANGES IN COMBINED BRAF/MEK INHIBITION WITH HIGH-DOSE HYDROXYCHLOROQUINE AS TREATMENT FOR ADVANCED METASTATIC BRAF MUTANT MELANOMA Preliminary Results From a Phase I/II Clinical Treatment Trial.